HNC, effect of cannabinoids in animal models

Disease modelTreatmentComparatorResultsRef.
Human head and neck squamous cell (FaDu), two tumour models; (1) subcutaneous xenograft; (2) tongue xenograft; BALB/c nude miceCBD 5 mg/kg p.o., 4 times per week, 4 weeks (s.c. xenograft) or CBD 5 mg/kg i.p., 3 times per week, for 4 weeks (tongue xenograft)

(1) Cisplatin 2.5 mg/kg i.p. once a week;

(2) CBD + cisplatin, (vs. control)

CBD slowed down the tumour increase of tongue xenografts; tumour volume after 3 weeks treatment with CBD was about 65% lower than of the controls, (cisplatin ~50%); the combination with cisplatin (5 mg CBD p.o. + 2.5 mg/kg cisplatin i.p.) decreased the tumour volume further (tumour volume ~15% of controls); tumour size was measured after three weeks[98]
UD-SCC-2 cells (HPV+), subcutaneous xenograft; nude miceTHC 3 mg/kg i.p., daily, 2 weeksControl: rimonabant (1 mg/kg) every other dayTHC 3 mg/kg per day, i.p., enhanced tumour growth by a factor of about 2, whereas cannabinoid receptor blockade (rimonabant) inhibits tumour growth[94]

p.o.: per os; ~: about